LONDON and PHILADELPHIA – December 8, 2025 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, expects to announce initial Faridoxorubicin Phase 1b data in the salivary gland cancer indication on December 17, 2025. A presentation will be made available via the Investor Meet Platform on December 17, 2025, at 10:00 AM GMT. The link to view the presentation is below. Investors can register for the webinar and submit questions through the platform link below at any time before the presentation.
https://www.investormeetcompany.com/avacta-group-plc/register